NCT03723564
Serial Amnioinfusions as Regenerative Therapy for Pulmonary Hypoplasia
At risk: Primary completion moved 2 years later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 11 versions: 9 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary completion pushed from Dec 31, 2026 to Dec 31, 2028
- Eligibility criteria expanded, about 17 words
- Study completion pushed from Dec 31, 2027 to Dec 31, 2029
- Study description revised
- Notable Primary completion date: Dec 31, 2025 to Dec 31, 2026
- Study completion date: Dec 31, 2026 to Dec 31, 2027
- Site contact updated
- Minor Site contact updatedv9
- Notable Primary completion date: Dec 31, 2023 to Dec 31, 2025
- Study completion date: Dec 31, 2025 to Dec 31, 2026
- Site contact updated
- Notable Primary completion date: Dec 31, 2022 to Dec 31, 2023
- Study completion date: Dec 31, 2024 to Dec 31, 2025
- Site contact updated
Show 3 earlier versionsHide 3 earlier versions
- Notable Lead sponsor: Rodrigo Ruano M.D., Ph.D to Mayo Clinic
- Site contact updated
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Start date changed from estimate of Nov 1, 2018 to Oct 1, 2018
- Notable Primary endpoints: 3 to 1
- Secondary endpoints: 1 to 2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Adverse Events
Timeframe: First amnioinfusion through delivery which may be up to 22 weeks.
Secondary (2)
Survival to renal transplant
Survival to dialysis
Arms and interventions
AmnioinfusionExperimental
Lactated Ringers Solution for Injection --- Serial ultrasound-guided amnioinfusion procedures will be performed on fetuses having severe LUTO or bilateral renal agenesis that are diagnosed between 18 0/7-25 6/7 weeks.
Drugs: Lactated Ringers Solution for Injection
Sites
1 site in 1 country
- Mayo ClinicRochester, Minnesota, United States